![](https://endpts.com/wp-content/uploads/2022/11/Fred-Aslan-Artiva-tile.jpg)
Fred Aslan, Artiva Biotherapeutics CEO
Artiva boasts early NK cell therapy results, giving lifeline to partner Affimed
Artiva Biotherapeutics reported early data on its off-the-shelf NK cell therapy in combination with rituximab, suggesting the combo could shrink tumors in non-Hodgkin lymphoma patients …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.